Recombinant Human MUC1 protein (ab80082)

Overview

Description

  • NatureRecombinant
  • SourceEscherichia coli
  • Amino Acid Sequence
    • AccessionP15941
    • SpeciesHuman
    • SequenceRPGSVVVQLTLAFREGTINVHDVETQFNQYKTEAASRYNLTISDVS
    • Molecular weight14 kDa including tags
    • Amino acids1095 to 1140
    • TagsHis tag N-Terminus
    • Additional sequence informationHis tag is 4kDa, Fusion protein size is 10 kDa.

Specifications

Our Abpromise guarantee covers the use of ab80082 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

  • Applications

    Western blot

    ELISA

    SDS-PAGE

  • FormLyophilised
  • Concentration information loading...

Preparation and Storage

  • Stability and Storage

    Shipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.

    Preservative: None
    Constituents: PBS

  • ReconstitutionRedissolve the powder with 1ml sterile water.

General Info

  • Alternative names
    • ADMCKD
    • ADMCKD1
    • Breast carcinoma associated antigen DF3
    • Breast carcinoma-associated antigen DF3
    • CA 15-3
    • CA15 3
    • CA15 3 antigen
    • CA15.3
    • Cancer antigen 15-3
    • Carcinoma associated mucin
    • Carcinoma-associated mucin
    • CD 227
    • CD227
    • DF3 antigen
    • EMA
    • Episialin
    • H23 antigen
    • H23AG
    • KL 6
    • KL-6
    • KL6
    • Krebs von den Lungen-6
    • MAM 6
    • MAM6
    • MCD
    • MCKD
    • MCKD1
    • Medullary cystic kidney disease 1 (autosomal dominant)
    • Medullary cystic kidney disease, autosomal dominant
    • MUC 1
    • MUC-1
    • MUC-1/SEC
    • MUC-1/X
    • MUC1
    • MUC1-alpha
    • MUC1-beta
    • MUC1-CT
    • MUC1-NT
    • MUC1/ZD
    • MUC1_HUMAN
    • Mucin 1
    • Mucin 1 transmembrane
    • Mucin 1, cell surface associated
    • Mucin-1 subunit beta
    • Peanut reactive urinary mucin
    • Peanut-reactive urinary mucin
    • PEM
    • PEMT
    • Polymorphic epithelial mucin
    • PUM
    • Tumor associated epithelial membrane antigen
    • Tumor associated epithelial mucin
    • Tumor associated mucin
    • Tumor-associated epithelial membrane antigen
    • Tumor-associated mucin
    see all
  • FunctionThe alpha subunit has cell adhesive properties. Can act both as an adhesion and an anti-adhesion protein. May provide a protective layer on epithelial cells against bacterial and enzyme attack.
    The beta subunit contains a C-terminal domain which is involved in cell signaling, through phosphorylations and protein-protein interactions. Modulates signaling in ERK, SRC and NF-kappa-B pathways. In activated T-cells, influences directly or indirectly the Ras/MAPK pathway. Promotes tumor progression. Regulates TP53-mediated transcription and determines cell fate in the genotoxic stress response. Binds, together with KLF4, the PE21 promoter element of TP53 and represses TP53 activity.
  • Tissue specificityExpressed on the apical surface of epithelial cells, especially of airway passages, breast and uterus. Also expressed in activated and unactivated T-cells. Overexpressed in epithelial tumors, such as breast or ovarian cancer and also in non-epithelial tumor cells. Isoform Y is expressed in tumor cells only.
  • Involvement in diseaseMUC1/CA 15-3 is used as a serological clinical marker of breast cancer to monitor response to breast cancer treatment and disease recurrence (PubMed:20816948). Decreased levels over time may be indicative of a positive response to treatment. Conversely, increased levels may indicate disease progression. At an early stage disease, only 21% of patients exhibit high MUC1/CA 15-3 levels, that is why CA 15-3 is not a useful screening test. Most antibodies target the highly immunodominant core peptide domain of 20 amino acid (APDTRPAPGSTAPPAHGVTS) tandem repeats. Some antibodies recognize glycosylated epitopes.
    Medullary cystic kidney disease 1
  • Sequence similaritiesContains 1 SEA domain.
  • Developmental stageDuring fetal development, expressed at low levels in the colonic epithelium from 13 weeks of gestation.
  • Post-translational
    modifications
    Highly glycosylated (N- and O-linked carbohydrates and sialic acid). O-glycosylated to a varying degree on serine and threonine residues within each tandem repeat, ranging from mono- to penta-glycosylation. The average density ranges from about 50% in human milk to over 90% in T47D breast cancer cells. Further sialylation occurs during recycling. Membrane-shed glycoproteins from kidney and breast cancer cells have preferentially sialyated core 1 structures, while secreted forms from the same tissues display mainly core 2 structures. The O-glycosylated content is overlapping in both these tissues with terminal fucose and galactose, 2- and 3-linked galactose, 3- and 3,6-linked GalNAc-ol and 4-linked GlcNAc predominating. Differentially O-glycosylated in breast carcinomas with 3,4-linked GlcNAc. N-glycosylation consists of high-mannose, acidic complex-type and hybrid glycans in the secreted form MUC1/SEC, and neutral complex-type in the transmembrane form, MUC1/TM.
    Proteolytic cleavage in the SEA domain occurs in the endoplasmic reticulum by an autoproteolytic mechanism and requires the full-length SEA domain as well as requiring a Ser, Thr or Cys residue at the P + 1 site. Cleavage at this site also occurs on isoform MUC1/X but not on isoform MUC1/Y. Ectodomain shedding is mediated by ADAM17.
    Dual palmitoylation on cysteine residues in the CQC motif is required for recycling from endosomes back to the plasma membrane.
    Phosphorylated on tyrosines and serine residues in the C-terminal. Phosphorylation on tyrosines in the C-terminal increases the nuclear location of MUC1 and beta-catenin. Phosphorylation by PKC delta induces binding of MUC1 to beta-catenin/CTNNB1 and thus decreases the formation of the beta-catenin/E-cadherin complex. Src-mediated phosphorylation inhibits interaction with GSK3B. Src- and EGFR-mediated phosphorylation on Tyr-1229 increases binding to beta-catenin/CTNNB1. GSK3B-mediated phosphorylation on Ser-1227 decreases this interaction but restores the formation of the beta-cadherin/E-cadherin complex. On T-cell receptor activation, phosphorylated by LCK. PDGFR-mediated phosphorylation increases nuclear colocalization of MUC1CT and CTNNB1.
    The N-terminal sequence has been shown to begin at position 24 or 28.
  • Cellular localizationSecreted; Cell membrane. Cytoplasm. Nucleus. On EGF and PDGFRB stimulation, transported to the nucleus through interaction with CTNNB1, a process which is stimulated by phosphorylation. On HRG stimulation, colocalizes with JUP/gamma-catenin at the nucleus and Apical cell membrane. Exclusively located in the apical domain of the plasma membrane of highly polarized epithelial cells. After endocytosis, internalized and recycled to the cell membrane. Located to microvilli and to the tips of long filopodial protusions.
  • Information by UniProt

Recombinant Human MUC1 protein images

  • 20% SDS PAGE showing ab80082 at approximately 10kDa.

References for Recombinant Human MUC1 protein (ab80082)

ab80082 has not yet been referenced specifically in any publications.

Product Wall

Thank you for contacting Abcam.

We have many antibodies against MUC1 in our catalogue, I have searched and found a few that may work for you, please see below:

http://www.abcam.com/MUC1-antibody-ab15481.html
http://www.abcam.co...

Read More

Thank you for your inquiry.

Unfortunately, we do not offer a MUC1 fulllength protein. The MUC1 protein (ab80082) is only a recombinant fragment and all others are peptides. I am sorry for the inconvenience but I cannot recommend any of these ...

Read More

Thank you for your inquiry and I sincerely apologize for the delay. I was in contact with the supplying lab and unfortunately we are not able to provide a custom preparation of this protein at this time. We also do not know if the MUC1 would bi...

Read More

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"